Based on UK Biobank findings for MLH1 and MSH2 (25), we suspect that path_PMS2 cancer risks in the general population are even lower than reported for PMS2-LS families and might fall well below the national threshold of three times the population CRC risk, therefore not warranting such surveillance. This evidence concerns the gene MSH2 and cancer.